methylsamidorphan
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01100151)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mu opioid receptorANTAGONIST
OPRM antagonist
Peripherally-restricted opioid receptor antagonist, affinity for OPRM1, OPRK1, OPRD1. Efficasy target OPRM1, no selectivity infomration found.
Chemistry & pharmacology
Loading structure…
SMILES
C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13- Mol. weight
- 385.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2364619 ↗
Also known as
- alks 37
- alks 37
- alks 37
- methylsamidorphan
- methylsamidorphan
- rdc-1036
- rdc-1036
- rdc-1036
- rdc-103600
- rdc-103600
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01418092 | Phase 2 | Sep 1, 2011 | Alkermes |
| NCT01382797 | Phase 2 | Aug 1, 2011 | Alkermes |
| NCT01100151 | Phase 2 | Apr 1, 2010 | Alkermes |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alkermes | For profit | 3 | 3 | 1 | 2010 |
1 organizations
Page 1 / 1